TY - JOUR
T1 - Novel markers of normal and neoplastic human plasmacytoid dendritic cells
AU - Marafioti, Teresa
AU - Paterson, Jennifer C.
AU - Ballabio, Erica
AU - Reichard, Kaaren K.
AU - Tedoldi, Sara
AU - Hollowood, Kevin
AU - Dictor, Michael
AU - Hansmann, Martin Leo
AU - Pileri, Stefano A.
AU - Dyer, Martin J.
AU - Sozzani, Silvano
AU - Dikic, Ivan
AU - Shaw, Andrey S.
AU - Petrella, Tony
AU - Stein, Harald
AU - Isaacson, Peter G.
AU - Facchetti, Fabio
AU - Mason, David Y.
PY - 2008/4/1
Y1 - 2008/4/1
N2 - Plasmacyloid dendritic cells (pDCs) are involved in innate immunity (eg, by secreting interferons) and also give rise to CD4+CD56+ hematodermic neoplasms. We report extensive characterization of human pDCs in routine tissue samples, documenting the expression of 19 immunohistologic markers, including signaling molecules (eg, BLNK), transcription factors (eg, ICSBP/IRF8 and PU.1), and Toll-like receptors (TLR7, TLR9). Many of these molecules are expressed in other cell types (principally B cells), but the adaptor protein CD2AP was essentially restricted to pDCs, and is therefore a novel immunohistologic marker for use in tissue biopsies. We found little evidence for activation-associated morphologic or phenotypic changes in conditions where pDCs are greatly increased (eg, Kikuchi disease). Most of the molecules were retained in the majority of pDC neoplasms, and 3 (BCL11A, CD2AP, and ICSBP/IRF8) were also commonly negative in leukemia cutis (acute myeloid leukemia in the skin), a tumor that may mimic pDC neoplasia. In summary, we have documented a range of molecules (notably those associated with B cells) expressed by pDCs in tissues and peripheral blood (where pDCs were detectable in cytospins at a frequency of <1% of mononuclear cells) and also defined potential new markers (in particular CD2AP) for the diagnosis of pDC tumors.
AB - Plasmacyloid dendritic cells (pDCs) are involved in innate immunity (eg, by secreting interferons) and also give rise to CD4+CD56+ hematodermic neoplasms. We report extensive characterization of human pDCs in routine tissue samples, documenting the expression of 19 immunohistologic markers, including signaling molecules (eg, BLNK), transcription factors (eg, ICSBP/IRF8 and PU.1), and Toll-like receptors (TLR7, TLR9). Many of these molecules are expressed in other cell types (principally B cells), but the adaptor protein CD2AP was essentially restricted to pDCs, and is therefore a novel immunohistologic marker for use in tissue biopsies. We found little evidence for activation-associated morphologic or phenotypic changes in conditions where pDCs are greatly increased (eg, Kikuchi disease). Most of the molecules were retained in the majority of pDC neoplasms, and 3 (BCL11A, CD2AP, and ICSBP/IRF8) were also commonly negative in leukemia cutis (acute myeloid leukemia in the skin), a tumor that may mimic pDC neoplasia. In summary, we have documented a range of molecules (notably those associated with B cells) expressed by pDCs in tissues and peripheral blood (where pDCs were detectable in cytospins at a frequency of <1% of mononuclear cells) and also defined potential new markers (in particular CD2AP) for the diagnosis of pDC tumors.
UR - http://www.scopus.com/inward/record.url?scp=43549106155&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=43549106155&partnerID=8YFLogxK
U2 - 10.1182/blood-2007-10-117531
DO - 10.1182/blood-2007-10-117531
M3 - Article
C2 - 18218851
AN - SCOPUS:43549106155
VL - 111
SP - 3778
EP - 3792
JO - Blood
JF - Blood
SN - 0006-4971
IS - 7
ER -